Pharmacokinetics and Safety of Pemafibrate in Patients with both Dyslipidemia and Severe Renal Impairment: A Phase 4 Study-Reference-Cited by-同舟云学术

Pharmacokinetics and Safety of Pemafibrate in Patients with both Dyslipidemia and Severe Renal Impairment: A Phase 4 Study

Published:2024 Issue: Volume: Page:
ISSN:1340-3478
Container-title:Journal of Atherosclerosis and Thrombosis
language:en
Short-container-title:JAT

Author:

Ishibashi Shun¹²,Arai Hidenori³,Yokote Koutaro⁴,Araki Eiichi⁵⁶,Watanabe Mao⁷,Nakanishi Michiko⁸,Makinose Yuichi⁹,Suganami Hideki¹⁰,Kurihara Yuji¹¹,Yamashita Shizuya¹²

Affiliation:

1. Division of Endocrinology and Metabolism, Department of Internal Medicine, School of Medicine, Jichi Medical University

2. Ishibashi Diabetes and Endocrine Clinic

3. National Center for Geriatrics and Gerontology

4. Chiba University

5. Kikuchi Medical Association Hospital

6. Research Center for Health and Sports Sciences, Kumamoto Health Science University

7. Medical Affairs Department, Kowa Company, Ltd.

8. Post Marketing Surveillance Department, Kowa Company, Ltd.

9. Clinical and non–Clinical Compliance Department, Kowa Company, Ltd.

10. Data Science Center, Kowa Company, Ltd.

11. PM and Training Department, Kowa AG Pharma Company, Ltd.

12. Department of Cardiology, Rinku General Medical Center

Publisher

Japan Atherosclerosis Society

Link

https://www.jstage.jst.go.jp/article/jat/advpub/0/advpub_64887/_pdf

Reference36 articles.

1. 1) Imai E, Horio M, Watanabe T, Iseki K, Yamagata K, Hara S, Ura N, Kiyohara Y, Moriyama T, Ando Y, Fujimoto S, Konta T, Yokoyama H, Makino H, Hishida A, and Matsuo S: Prevalence of chronic kidney disease in the Japanese general population [published correction appears in Clin Exp Nephrol, 2009; 13: 631-632]. Clin Exp Nephrol, 2009; 13: 621-630

2. 2) Webster AC, Nagler EV, Morton RL, and Masson P: Chronic kidney disease. Lancet, 2017; 389: 1238-1252

3. 3) Noels H, Lehrke M, Vanholder R, and Jankowski J: Lipoproteins and fatty acids in chronic kidney disease: molecular and metabolic alterations. Nat Rev Nephrol, 2021; 17: 528-542

4. 4) Ferro CJ, Mark PB, Kanbay M, Sarafidis P, Heine GH, Rossignol P, Massy ZA, Mallamaci F, Valdivielso JM, Malyszko J, Verhaar MC, Ekart R, Vanholder R, London G, Ortiz A, and Zoccali C: Lipid management in patients with chronic kidney disease [published correction appears in Nat Rev Nephrol, 2019; 15: 121]. Nat Rev Nephrol, 2018; 14: 727-749

5. 5) Speer T, Ridker PM, von Eckardstein A, Schunk SJ, and Fliser D: Lipoproteins in chronic kidney disease: from bench to bedside. Eur Heart J, 2021; 42: 2170-2185